Australia's most trusted
source of pharma news
Sunday, 14 December 2025
Posted 5 December 2016
Last week Australia saw the first PBS listing of a PCSK9 inhibitor, the new class of cholesterol-lowering biologics that hold out some hope for a revival in the cardiovascular market in 2017.
Amgen's Repatha (evolocumab) was listed on 1 December but, since its approval in May this year, Sanofi's rival class member Praluent (alirocumab) has been notably absent from the submission lists.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.